Fecal Metagenomics Spots Colorectal Cancer Markers Before Symptoms Appear

Colorectal cancer kills more people worldwide than almost any other malignancy, yet catching it early still depends heavily on colonoscopy, a procedure many patients avoid. A preliminary study published in Frontiers in Cellular and Infection Microbiology by Zehui Gu and colleagues proposes a different approach: read the bacterial DNA in a stool sample, look for specific microbial imbalances and gene signatures, and flag patients who may have stage I or II colorectal cancer before symptoms emerge. The findings are early and come from a small cohort, but the detail of the microbial portrait is striking.

Faecalibacterium Depletion and Shigella Enrichment in CRC Stool Samples

The most consistent signal in the data was a sharp drop in bacteria associated with a healthy colon. Fecal samples from 20 stage I or II colorectal cancer (CRC) patients showed significantly lower alpha diversity than samples from 11 healthy volunteers, with Shannon and Simpson indices both reaching statistical significance (p = 0.014 and p = 0.0099, respectively). Beta diversity analysis confirmed the two groups clustered apart (stress = 0.1308, p = 0.021), meaning the overall community structure, not just individual species counts, differed reliably between cases and controls.

Cancer patients had higher stool abundance of Shigella, Porphyromonas, Proteus, Bacteroides, Alistipes, Fusobacterium, and Escherichia. Healthy controls, by contrast, carried more Eubacterium, Faecalibacterium, Blautia, Roseburia, and Prevotella: genera that produce short-chain fatty acids such as butyrate, which help regulate immune responses and suppress early tumor formation. Faecalibacterium, a primary butyrate producer with documented anti-inflammatory and anti-tumor effects, returned an area under the receiver operating curve (AUC) of 1.000 in this sample, making it the single most discriminating candidate biomarker. The authors are candid that an AUC of 1.000 in 31 participants almost certainly reflects overfitting, and independent validation is the obvious next step.

This pattern of pro-inflammatory taxa rising while butyrate producers fall mirrors what earlier shotgun sequencing studies have documented across different populations and labs, suggesting the signal is real even if the exact species list shifts by cohort.

Why These Bacterial Shifts Could Accelerate Tumor Growth

The microbial changes are not merely correlational bystanders. Alistipes and Odoribacter, both elevated in CRC patients, are influenced by high-fat diets and produce sulfonolipids that activate TLR4 signaling, a pathway linked to inflammatory bowel disease and chronic gut inflammation. Shigella and certain enteroinvasive Escherichia coli strains can acquire genomic deletions that enhance their virulence, allowing deeper epithelial invasion. Fusobacterium nucleatum, long flagged in early-onset CRC microbial signatures, is well documented for its ability to promote the Wnt signaling cascade that drives colorectal tumor growth.

Meanwhile, the loss of Faecalibacterium, Blautia, and Roseburia removes a key brake on inflammation. These genera supply the colonocytes that line the gut wall with butyrate, the short-chain fatty acid that suppresses proliferative signaling and nudges pre-cancerous cells toward apoptosis. When that supply dries up, the epithelium becomes more vulnerable to the carcinogenic pressures the remaining dysbiotic community is exerting.

Four Microbial Genes That Distinguish CRC from Healthy Stool

Beyond species counts, the study examined functional genes in the metagenomic reads and found four that separated groups in ways not previously reported together. LptA, a periplasmic protein involved in lipopolysaccharide export, was elevated in CRC samples; disrupting LptA is known to inhibit gram-negative bacterial growth, and its overrepresentation may reflect the gram-negative-heavy dysbiotic community in cancer patients. tnaA, encoding tryptophanase, was also elevated; this enzyme degrades tryptophan and can modulate immune tolerance in the gut. envC, which encodes an E. coli cell-wall hydrolase activator, was likewise higher in CRC.

ArgB, which encodes acetylglutamate kinase and catalyzes a step in arginine biosynthesis, ran in the opposite direction: lower in CRC patients. That finding connects to a known phenomenon in colorectal tumors called arginine auxotrophy, where cancer cells down-regulate the enzyme ASS and become dependent on external arginine supply. The reduced argB signal in the microbiome may reflect that altered metabolic demand. The authors flag all four genes as candidates for therapeutic targets or predictive biomarkers, though mechanistic studies are needed to establish causality.

The team also found 42 differences in carbohydrate-active enzymes and 38 differences in antibiotic resistance gene ontologies between groups, hinting that the metabolic and ecological disruption in CRC gut communities extends well beyond any single pathway.

Small Sample Size Limits How Far These Results Can Travel

The study enrolled 31 people total: 20 CRC patients and 11 healthy controls. That is enough to generate hypotheses and identify candidate markers, but far too few to build a clinically deployable test. The authors are explicit about this: the absence of an independent test set means the diagnostic model, which incorporates 18 specific genera, has not been validated outside the discovery cohort. The AUC of 1.000 for Faecalibacterium is the clearest warning sign of overfitting.

Translating microbiome findings into routine clinical screening faces additional structural barriers beyond sample size: methodological variability between labs, inconsistent bioinformatics pipelines, and the underrepresentation of non-Western populations in reference databases all complicate generalization. The current cohort was drawn from a single hospital in Jinzhou, China, and may not reflect the microbial diversity seen in patients elsewhere.

The team notes that future work should expand the cohort to include patients with enteritis, intestinal polyps, and tubular adenomas, the precancerous lesions that precede frank malignancy. Including those intermediate states would let researchers test whether the microbial and gene signatures appear before cancer is detectable by other means, which is ultimately the question that matters for screening.

Non-Invasive CRC Screening Through Fecal Metagenomics

If the microbial and gene signatures survive replication in larger, independent cohorts, the practical payoff could be significant. Colonoscopy remains the gold standard for CRC detection but carries real barriers: patient discomfort, procedural risk, and limited access in many health systems. Fecal immunochemical testing is non-invasive but misses a meaningful fraction of early-stage cancers. A metagenomic stool test that reliably flagged stage I or II disease would slot neatly into screening programs as a pre-colonoscopy triage tool.

Broader microbiome-targeted strategies for CRC, including probiotics designed to restore butyrate producers and dietary interventions aimed at reversing dysbiosis, are already under investigation in parallel. The gene-level findings from this study, particularly the argB and LptA signals, suggest that therapeutic strategies might eventually target the functional output of the microbiome rather than species composition alone. For now, the Gu et al. paper is best read as a detailed, carefully hedged proof of concept: the gut microbiome in early CRC is measurably different from a healthy one, and metagenomic sequencing can see those differences in a sample that requires no procedure beyond a bathroom visit.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• Very small sample size (20 CRC patients, 11 healthy controls) severely limits the reliability and generalizability of findings.
• The reported AUC of 1.000 for Faecalibacterium as a diagnostic biomarker almost certainly reflects overfitting at this sample size and should not be taken at face value.
• This is an observational study — it identifies associations between gut microbiome composition and colorectal cancer, not causal relationships.
• No independent validation cohort was used, so the diagnostic model's real-world performance is unknown.
• Funding source was not disclosed by the authors.

Single-centre observational metagenomic study comparing fecal microbiome composition between 20 early-stage colorectal cancer patients and 11 healthy controls. The study identifies associations between specific microbial genera and cancer status but cannot establish causation. The very small sample, absence of an independent validation cohort, and a suspiciously perfect AUC for one biomarker candidate indicate findings require replication in substantially larger, independent populations before clinical relevance can be assessed.

References

1. Zehui Gu, Qi Tan, Dong Mao, et al. (2026). Metagenomic analysis of human feces reveals gut microbiome role in colorectal cancer. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1828012
2. Adzhar Rambli, Ali H. M. Abuzaid, Ibrahim Bin Mohamed, Abdul Ghapor Hussin (2016). Procedure for Detecting Outliers in a Circular Regression Model. PLOS ONE. https://doi.org/10.1371/journal.pone.0153074
3. Sara Lauricella, Francesco Brucchi, Roberto Cirocchi, Diletta Cassini, Marco Vitellaro (2025). The Gut Microbiome in Early-Onset Colorectal Cancer: Distinct Signatures, Targeted Prevention and Therapeutic Strategies. Journal of Personalized Medicine. https://doi.org/10.3390/jpm15110552
4. Henok Ayalew Tegegne, Tor C. Savidge (2025). G ut microbiome metagenomics in clinical practice: bridging the gap between research and precision medicine. Gut Microbes. https://doi.org/10.1080/19490976.2025.2569739
5. Miriam Tudorache, Andreea-Ramona Treteanu, Gratiela Gradisteanu Pircalabioru, Irina-Oana Lixandru-Petre, Alexandra Bolocan, Octavian Andronic (2025). Gut Microbiome Alterations in Colorectal Cancer: Mechanisms, Therapeutic Strategies, and Precision Oncology Perspectives. Cancers. https://doi.org/10.3390/cancers17142294